162 related articles for article (PubMed ID: 21327452)
1. Overexpression of Galectin-3 and its clinical significance in ovarian carcinoma.
Kim MK; Sung CO; Do IG; Jeon HK; Song TJ; Park HS; Lee YY; Kim BG; Lee JW; Bae DS
Int J Clin Oncol; 2011 Aug; 16(4):352-8. PubMed ID: 21327452
[TBL] [Abstract][Full Text] [Related]
2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
3. High galectin-1 expression correlates with poor prognosis and is involved in epithelial ovarian cancer proliferation and invasion.
Kim HJ; Jeon HK; Cho YJ; Park YA; Choi JJ; Do IG; Song SY; Lee YY; Choi CH; Kim TJ; Bae DS; Lee JW; Kim BG
Eur J Cancer; 2012 Aug; 48(12):1914-21. PubMed ID: 22386573
[TBL] [Abstract][Full Text] [Related]
4. Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF-κB pathway.
Lu H; Liu Y; Wang D; Wang L; Zhou H; Xu G; Xie L; Wu M; Lin Z; Yu Y; Li G
Tumour Biol; 2016 Aug; 37(8):11469-77. PubMed ID: 27012551
[TBL] [Abstract][Full Text] [Related]
5. Galectins-1, -3, and -7 Are Prognostic Markers for Survival of Ovarian Cancer Patients.
Schulz H; Schmoeckel E; Kuhn C; Hofmann S; Mayr D; Mahner S; Jeschke U
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28594391
[TBL] [Abstract][Full Text] [Related]
6. Galectin-3 regulates chemotherapy sensitivity in epithelial ovarian carcinoma via regulating mitochondrial function.
Wang D; You D; Li L
J Toxicol Sci; 2019; 44(1):47-56. PubMed ID: 30626779
[TBL] [Abstract][Full Text] [Related]
7. Pectasol-C Modified Citrus Pectin targets Galectin-3-induced STAT3 activation and synergize paclitaxel cytotoxic effect on ovarian cancer spheroids.
Hossein G; Halvaei S; Heidarian Y; Dehghani-Ghobadi Z; Hassani M; Hosseini H; Naderi N; Sheikh Hassani S
Cancer Med; 2019 Aug; 8(9):4315-4329. PubMed ID: 31197964
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of galectin-7 in epithelial ovarian cancer.
Kim HJ; Jeon HK; Lee JK; Sung CO; Do IG; Choi CH; Kim TJ; Kim BG; Bae DS; Lee JW
Anticancer Res; 2013 Apr; 33(4):1555-61. PubMed ID: 23564797
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor C enhances cervical cancer cell invasiveness via upregulation of galectin-3 protein.
Liu J; Cheng Y; He M; Yao S
Gynecol Endocrinol; 2014 Jun; 30(6):461-5. PubMed ID: 24650367
[TBL] [Abstract][Full Text] [Related]
10. High claudin-7 expression is associated with a poor response to platinum-based chemotherapy in epithelial ovarian carcinoma.
Kim CJ; Lee JW; Choi JJ; Choi HY; Park YA; Jeon HK; Sung CO; Song SY; Lee YY; Choi CH; Kim TJ; Lee JH; Kim BG; Bae DS
Eur J Cancer; 2011 Apr; 47(6):918-25. PubMed ID: 21134740
[TBL] [Abstract][Full Text] [Related]
11. Elevated nm23 protein expression is correlated with diminished progression-free survival in patients with epithelial ovarian carcinoma.
Srivatsa PJ; Cliby WA; Keeney GL; Dodson MK; Suman VJ; Roche PC; Podratz KC
Gynecol Oncol; 1996 Mar; 60(3):363-72. PubMed ID: 8774640
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma.
Chang B; Meng J; Zhu H; Du X; Sun L; Wang L; Li S; Yang G
Diagn Pathol; 2018 Nov; 13(1):87. PubMed ID: 30428884
[TBL] [Abstract][Full Text] [Related]
13. Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors.
Ajani JA; Estrella JS; Chen Q; Correa AM; Ma L; Scott AW; Jin J; Liu B; Xie M; Sudo K; Shiozaki H; Badgwell B; Weston B; Lee JH; Bhutani MS; Onodera H; Suzuki K; Suzuki A; Ding S; Hofstetter WL; Johnson RL; Bresalier RS; Song S
Br J Cancer; 2018 Jan; 118(1):52-61. PubMed ID: 29136404
[TBL] [Abstract][Full Text] [Related]
14. Expression and functions of galectin-7 in ovarian cancer.
Labrie M; Vladoiu MC; Grosset AA; Gaboury L; St-Pierre Y
Oncotarget; 2014 Sep; 5(17):7705-21. PubMed ID: 25277199
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
[TBL] [Abstract][Full Text] [Related]
16. Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma.
Lee YY; Jeon HK; Hong JE; Cho YJ; Ryu JY; Choi JJ; Lee SH; Yoon G; Kim WY; Do IG; Kim MK; Kim TJ; Choi CH; Lee JW; Bae DS; Kim BG
Oncotarget; 2015 Oct; 6(33):35040-50. PubMed ID: 26418900
[TBL] [Abstract][Full Text] [Related]
17. Defective expression of Protein 4.1N is correlated to tumor progression, aggressive behaviors and chemotherapy resistance in epithelial ovarian cancer.
Xi C; Ren C; Hu A; Lin J; Yao Q; Wang Y; Gao Z; An X; Liu C
Gynecol Oncol; 2013 Dec; 131(3):764-71. PubMed ID: 23994105
[TBL] [Abstract][Full Text] [Related]
18. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
[No Abstract] [Full Text] [Related]
19. CDKN3 is an independent prognostic factor and promotes ovarian carcinoma cell proliferation in ovarian cancer.
Li T; Xue H; Guo Y; Guo K
Oncol Rep; 2014 Apr; 31(4):1825-31. PubMed ID: 24573179
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of galectin-3 in pituitary tumors.
Riss D; Jin L; Qian X; Bayliss J; Scheithauer BW; Young WF; Vidal S; Kovacs K; Raz A; Lloyd RV
Cancer Res; 2003 May; 63(9):2251-5. PubMed ID: 12727847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
